Biocardia announces dsmb recommendation to pause new enrollment in phase iii pivotal cardiamp cell therapy heart failure trial while additional blinded data is collected

Sunnyvale, calif., july 24, 2023 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent data safety monitoring board (dsmb) has completed its prespecified data review for the ongoing phase iii pivotal  cardiamp ®  cell therapy heart failure trial (clinicaltrials.gov identifier: nct02438306), for which fda granted breakthrough designation. pursuant to the dsmb recommendation, biocardia is pausing the trial pending the one-year follow-up outcomes analysis for patients that have been treated and those that have been enrolled but not yet treated.
BCDA Ratings Summary
BCDA Quant Ranking